India · Delayed Price · Currency is INR Clean Science and Technology Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY 2026 saw sequential revenue and margin improvement, led by record HALS sales and strong export growth. Backward integration and capacity expansion are underway, while global volatility and competition remain key risks. Dividend of INR 4/share declared.
-
Q3 FY26 saw revenue and margins decline due to weak demand, pricing pressure, and tariffs, but HALS business grew 55% YoY and new plants are expected to improve margins. CapEx projects are on track, and management remains focused on long-term growth despite ongoing market headwinds.
-
Revenue and PAT declined sequentially and year-over-year due to lower sales and forex loss, but EBITDA margins remained robust. Health segment volumes grew over 25% sequentially, with new products and capacity expansions expected to drive growth in Q4.
-
Q1 FY26 saw resilient margins despite a 9% sequential revenue drop, with record-high standalone EBITDA margin over 46%. New product launches and CapEx investments are set to drive growth, though guidance is moderated to 15%-18% EBITDA growth for FY26.
Fiscal Year 2025
-
Record sales volumes and strong R&D drove FY 2025 growth, with HALS and performance chemicals expanding the addressable market. EBITDA margins remained robust at 41–44%, and significant CAPEX supports new product launches and future growth.
-
Q3FY25 delivered strong volume-led growth and robust margins, with all major product lines commercialized and global distribution networks established. New products and capacity expansions are set to drive further revenue and margin improvements in FY26.
-
Q2 FY25 delivered strong volume-led growth with sales up 26% and PAT up 30% year-over-year, driven by robust performance in chemicals and new product launches. EBITDA margin remained high at 42%, while significant CapEx and capacity ramp-ups are set to fuel further expansion.
-
Q1 FY25 delivered 16% year-over-year sales growth and 23% PAT growth, driven by strong volumes and margin expansion. New HALS products were commercialized, CapEx projects advanced, and capacity utilization is set to rise, supporting future profitability.